Leprosy, tuberculoid
Chapter 1:Certain infectious and parasitic diseases
ICD-10 A30.3 is a billable code used to indicate a diagnosis of leprosy, tuberculoid.
Tuberculoid leprosy is a form of leprosy characterized by a strong immune response to the Mycobacterium leprae bacteria, leading to localized skin lesions and nerve damage. Patients typically present with one or more hypopigmented or erythematous skin patches that may be numb due to peripheral nerve involvement. The lesions are often well-defined and may exhibit hair loss. Tuberculoid leprosy is less contagious than other forms of leprosy, such as lepromatous leprosy, due to the robust immune response that limits the spread of the bacteria. Diagnosis is primarily clinical, supported by skin smears or biopsies showing granulomatous inflammation and acid-fast bacilli. Treatment involves multi-drug therapy (MDT) with rifampicin and dapsone, typically administered for 6-12 months. Early diagnosis and treatment are crucial to prevent disability and complications associated with nerve damage. Resistance to treatment is rare, but monitoring for adverse effects and adherence to therapy is essential for successful outcomes.
Detailed clinical notes on symptoms, diagnostic tests, and treatment plans.
Diagnosis and management of leprosy cases, monitoring treatment response.
Ensure accurate documentation of the immune response and any complications.
Photographic evidence of skin lesions, biopsy results, and treatment history.
Evaluation of skin lesions suspected to be leprosy, management of skin manifestations.
Differentiation from other dermatological conditions is crucial.
Used when a biopsy is performed to confirm diagnosis.
Include detailed pathology report and clinical notes.
Ensure the biopsy is linked to the diagnosis of leprosy.
The primary treatment for tuberculoid leprosy is multi-drug therapy (MDT) consisting of rifampicin and dapsone, typically administered for 6-12 months.
